Objective: This study compares the efficacy and safety of Jintrolong with other long-acting growth hormones (LAGHs) and daily growth hormone (GH) in pediatric growth hormone deficiency (GHD).Methods: English and Chinese databases were comprehensively searched from inception to 30 June 2025.Efficacy outcomes were height velocity (HV), change in HV (cHV), and change in height standard deviation score (cHSDS).Safety outcomes were adverse events (AEs) and serious AEs (SAEs).Results: Among the 5 studies included, Jintrolong showed better effect on HV (mean difference MD, 0.86 cm/year; 95% confidence interval CI, 0.13 to 1.6) than pegpesen (MD, -0.10 cm/year; 95% CI, -0.53 to 0.32) and somapacitan (MD, -0.030 cm/year; 95% CI, -0.52 to 0.46) compared with daily GH.Similarly, for cHV and cHSDS, Jintrolong demonstrated a statistically significant improvement compared with daily GH (cHV: MD, 0.84 cm/year; 95% CI, 0.077 to 1.60; cHSDS: MD, 0.080; 95% CI, 0.0013 to 0.16).No significant differences were reported in the incidence of AEs and SAEs among Jintrolong (AE: risk ratio RR, 1.0; 95% CI, 0.77 to 1.4; SAE: RR, 0.0049; 95% CI, ~0 to 3,216,099.58),pegpesen (AE: RR, 1.0; 95% CI, 0.54 to 1.8; SAE: RR, 1.3; 95% CI, 0.03 to 42.34), somapacitan (AE: RR, 1.1; 95% CI, 0.99 to 1.3; SAE: RR, 2.6; 95% CI, 0.82 to 12), compared with daily rhGH. Conclusion:Jintrolong showed more favorable growth responses in 52 weeks compared with other LAGHs and daily GH without increasing safety risks.
Liu et al. (2026) studied this question.